Seres Therapeutics’ SER-155 Secures the US FDA’s Breakthrough Therapy Designation to Reduce Bloodstream Infections
Shots:
- The US FDA has granted BTD to SER-155 for reducing bloodstream infections (BSIs) in adults, receiving allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies
- Designation was based on P-Ib study of SER-155 vs PBO, showing a 77% reduction in bacterial BSIs (10% vs 42.9%), shorter period of antibiotic use (9.2 vs 21.1 days) and reduced febrile neutropenia & gastrointestinal pathogen domination. Seres is looking for a collaboration to support its development
- SER-155 (oral) is a biotherapeutic aimed at preventing bacterial bloodstream infections and AMR-related outcomes in allo-HSCT patients by decolonizing GI pathogens and improving immune tolerance
Ref: Seres Therapeutics | Image: Seres Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
